Trial Profile
A Phase IB Combination Study of MEK Inhibitor GSK1120212 With Gemcitabine in Subjects With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Trametinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 08 Sep 2011 New trial record